SG11201810040WA - Direct selection of cells expressing high levels of heteromeric proteins using glutamine synthetase intragenic complementation vectors - Google Patents
Direct selection of cells expressing high levels of heteromeric proteins using glutamine synthetase intragenic complementation vectorsInfo
- Publication number
- SG11201810040WA SG11201810040WA SG11201810040WA SG11201810040WA SG11201810040WA SG 11201810040W A SG11201810040W A SG 11201810040WA SG 11201810040W A SG11201810040W A SG 11201810040WA SG 11201810040W A SG11201810040W A SG 11201810040WA SG 11201810040W A SG11201810040W A SG 11201810040WA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- california
- thousand oaks
- street
- pct
- Prior art date
Links
- 239000013598 vector Substances 0.000 title abstract 3
- 102000004169 proteins and genes Human genes 0.000 title abstract 2
- 108090000623 proteins and genes Proteins 0.000 title abstract 2
- 102000005396 glutamine synthetase Human genes 0.000 title 1
- 108020002326 glutamine synthetase Proteins 0.000 title 1
- 241000219492 Quercus Species 0.000 abstract 4
- 229920001184 polypeptide Polymers 0.000 abstract 3
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 3
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 3
- 210000004027 cell Anatomy 0.000 abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 102000003960 Ligases Human genes 0.000 abstract 1
- 108090000364 Ligases Proteins 0.000 abstract 1
- 210000004102 animal cell Anatomy 0.000 abstract 1
- 238000004113 cell culture Methods 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 238000003259 recombinant expression Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
- C12N15/1055—Protein x Protein interaction, e.g. two hybrid selection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
- C07K16/065—Purification, fragmentation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/65—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression using markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/67—General methods for enhancing the expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/93—Ligases (6)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y104/00—Oxidoreductases acting on the CH-NH2 group of donors (1.4)
- C12Y104/01—Oxidoreductases acting on the CH-NH2 group of donors (1.4) with NAD+ or NADP+ as acceptor (1.4.1)
- C12Y104/01002—Glutamate dehydrogenase (1.4.1.2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y603/00—Ligases forming carbon-nitrogen bonds (6.3)
- C12Y603/04—Other carbon-nitrogen ligases (6.3.4)
- C12Y603/04004—Adenylosuccinate synthase (6.3.4.4)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y603/00—Ligases forming carbon-nitrogen bonds (6.3)
- C12Y603/04—Other carbon-nitrogen ligases (6.3.4)
- C12Y603/04005—Argininosuccinate synthase (6.3.4.5)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
- C12N2015/8518—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic expressing industrially exogenous proteins, e.g. for pharmaceutical use, human insulin, blood factors, immunoglobulins, pseudoparticles
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y603/00—Ligases forming carbon-nitrogen bonds (6.3)
- C12Y603/01—Acid-ammonia (or amine)ligases (amide synthases)(6.3.1)
- C12Y603/01002—Glutamate-ammonia ligase (6.3.1.2)
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Computational Biology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Enzymes And Modification Thereof (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662334966P | 2016-05-11 | 2016-05-11 | |
| PCT/US2017/032139 WO2017197098A1 (en) | 2016-05-11 | 2017-05-11 | Direct selection of cells expressing high levels of heteromeric proteins using glutamine synthetase intragenic complementation vectors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201810040WA true SG11201810040WA (en) | 2018-12-28 |
Family
ID=58873869
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201810040WA SG11201810040WA (en) | 2016-05-11 | 2017-05-11 | Direct selection of cells expressing high levels of heteromeric proteins using glutamine synthetase intragenic complementation vectors |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US11384140B2 (enExample) |
| EP (2) | EP3455359B1 (enExample) |
| JP (2) | JP6972022B2 (enExample) |
| KR (2) | KR102323519B1 (enExample) |
| CN (2) | CN115873904A (enExample) |
| AU (2) | AU2017263454B2 (enExample) |
| BR (1) | BR112018073316A2 (enExample) |
| CA (1) | CA3024027A1 (enExample) |
| CL (1) | CL2018003210A1 (enExample) |
| EA (1) | EA201892588A1 (enExample) |
| ES (1) | ES2914118T3 (enExample) |
| IL (2) | IL300591A (enExample) |
| MA (1) | MA44976A (enExample) |
| MX (2) | MX394682B (enExample) |
| SG (1) | SG11201810040WA (enExample) |
| TW (2) | TWI757291B (enExample) |
| WO (1) | WO2017197098A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018093331A1 (en) * | 2016-11-16 | 2018-05-24 | Agency For Science, Technology And Research | Attenuated glutamine synthetase as a selection marker |
| BR112019024750A2 (pt) | 2017-05-24 | 2020-06-09 | Thoeris Gmbh | uso de glutamina sintetase no tratamento da hiperamonemia |
| CN109988777A (zh) * | 2017-12-29 | 2019-07-09 | 南京金斯瑞生物科技有限公司 | 谷氨酰胺合成酶基因以及应用 |
| SG11202109642SA (en) * | 2019-05-07 | 2021-10-28 | Amgen Inc | Vectors and expression systems for producing recombinant proteins |
| WO2023011442A1 (en) * | 2021-08-03 | 2023-02-09 | Shanghai Zhenge Biotechnology Co., Ltd. | Selectable markers for eukaryotic expression system |
| CN118804978A (zh) * | 2021-12-27 | 2024-10-18 | 上海臻格生物技术有限公司 | 用于重组生产系统的新型标志物 |
| EP4496884A1 (en) * | 2022-03-23 | 2025-01-29 | Boehringer Ingelheim International Gmbh | New glutamine synthetase variants as selection marker |
| AU2023238775A1 (en) | 2022-03-23 | 2024-10-31 | Boehringer Ingelheim International Gmbh | Bacterial glutamine synthetase as selection marker in mammalian cells |
| WO2025037708A1 (en) * | 2023-08-16 | 2025-02-20 | Korea Advanced Institute Of Science And Technology | Method for selection of cell line expressing high levels of recombinant protein using glutamine synthetase split expression vector |
| WO2025128343A1 (en) | 2023-12-11 | 2025-06-19 | Just-Evotec Biologics, Inc. | Protein expression using trans-splicing and split selectable markers |
| CN118006685B (zh) * | 2024-04-07 | 2024-07-23 | 上海碧博生物医药科技有限公司 | 一种快速的高表达单克隆细胞株构建方法 |
| WO2025250814A1 (en) * | 2024-05-31 | 2025-12-04 | Amgen Inc. | Intein based split glutamine synthetase engineering |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| JPH0819508B2 (ja) | 1987-08-19 | 1996-02-28 | 三菱マテリアル株式会社 | Ｆｅ−Ｃｏ基合金製高周波用磁芯材 |
| IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
| GB9014932D0 (en) | 1990-07-05 | 1990-08-22 | Celltech Ltd | Recombinant dna product and method |
| DE69233482T2 (de) | 1991-05-17 | 2006-01-12 | Merck & Co., Inc. | Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen |
| WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
| US5624818A (en) | 1991-09-09 | 1997-04-29 | Fred Hutchinson Cancer Research Center | Nucleic acids encoding regulatory proteins that dimerize with Mad or Max |
| CA2121798C (en) | 1991-10-25 | 2007-07-24 | Richard J. Armitage | Novel cytokine |
| JPH05244982A (ja) | 1991-12-06 | 1993-09-24 | Sumitomo Chem Co Ltd | 擬人化ｂ−ｂ１０ |
| US5573925A (en) | 1994-11-28 | 1996-11-12 | The Wistar Institute Of Anatomy And Biology | P53 proteins with altered tetramerization domains |
| CA2222914C (en) | 1995-06-07 | 2002-04-02 | Immunex Corporation | Novel cd40l mutein |
| US5916771A (en) | 1996-10-11 | 1999-06-29 | Abgenix, Inc. | Production of a multimeric protein by cell fusion method |
| US6342345B1 (en) | 1997-04-02 | 2002-01-29 | The Board Of Trustees Of The Leland Stanford Junior University | Detection of molecular interactions by reporter subunit complementation |
| GB9722131D0 (en) | 1997-10-20 | 1997-12-17 | Medical Res Council | Method |
| DK1196566T3 (da) * | 1999-07-12 | 2006-06-06 | Genentech Inc | Ekspressionsvektorer og -metoder |
| GB9928787D0 (en) | 1999-12-03 | 2000-02-02 | Medical Res Council | Direct screening method |
| GB0025144D0 (en) | 2000-10-13 | 2000-11-29 | Medical Res Council | Concatenated nucleic acid sequences |
| PT1434871T (pt) * | 2001-09-20 | 2017-04-05 | Immunex Corp | Seleção de células que expressam polipéptidos heteroméricos |
| GB0200977D0 (en) * | 2002-01-17 | 2002-03-06 | Lonza Biologics Plc | Glutamine-auxotrophic human cells capable of producing proteins and capable of growing in a glutamine-free medium |
| WO2004038003A2 (en) * | 2002-10-25 | 2004-05-06 | Five Prime Therapeutics, Inc. | Human polypeptides encoded by polynucleotides and methods of their use |
| US7384744B2 (en) * | 2002-11-29 | 2008-06-10 | Boehringer Ingelheim Pharma Gmbh & Co., Kg | Expression vector, methods for the production of heterologous gene products and for the selection of recombinant cells producing high levels of such products |
| US20040202995A1 (en) | 2003-04-09 | 2004-10-14 | Domantis | Nucleic acids, proteins, and screening methods |
| US7674618B2 (en) * | 2003-09-04 | 2010-03-09 | Medarex, Inc. | Expression vector |
| WO2006036834A2 (en) | 2004-09-24 | 2006-04-06 | Amgen Inc. | MODIFIED Fc MOLECULES |
| US8053238B2 (en) | 2005-10-31 | 2011-11-08 | Unhwa Corporation | Isolated population of plant single cells and method of preparing the same |
| US20070254338A1 (en) * | 2006-04-24 | 2007-11-01 | Amgen Inc. | Method for making recombinant protein using complementation dependent DHFR mutants |
| WO2008154014A2 (en) | 2007-06-11 | 2008-12-18 | Amgen Inc. | A method for culturing mammalian cells to improve recombinant protein production |
| WO2012027533A1 (en) * | 2010-08-25 | 2012-03-01 | Gt Life Sciences, Inc. | Selectable markers and related methods |
| US20130244231A1 (en) * | 2010-11-08 | 2013-09-19 | Jcr Pharmaceuticals Co., Ltd. | Novel expression vector |
| WO2012095514A1 (en) * | 2011-01-14 | 2012-07-19 | Vivalis | Recombinant protein production system |
| WO2012145682A1 (en) | 2011-04-21 | 2012-10-26 | Amgen Inc. | A method for culturing mammalian cells to improve recombinant protein production |
| AU2012203048A1 (en) * | 2011-05-24 | 2012-12-13 | Agency For Science, Technology And Research | IRES mediated multicistronic vectors |
| KR101411740B1 (ko) * | 2012-05-29 | 2014-06-27 | 한화케미칼 주식회사 | 항체 발현용 바이시스트로닉 발현벡터 및 이를 이용한 항체의 생산 방법 |
-
2017
- 2017-05-11 BR BR112018073316A patent/BR112018073316A2/pt not_active Application Discontinuation
- 2017-05-11 WO PCT/US2017/032139 patent/WO2017197098A1/en not_active Ceased
- 2017-05-11 JP JP2018559814A patent/JP6972022B2/ja active Active
- 2017-05-11 MA MA044976A patent/MA44976A/fr unknown
- 2017-05-11 MX MX2018013882A patent/MX394682B/es unknown
- 2017-05-11 ES ES17727027T patent/ES2914118T3/es active Active
- 2017-05-11 EA EA201892588A patent/EA201892588A1/ru unknown
- 2017-05-11 AU AU2017263454A patent/AU2017263454B2/en active Active
- 2017-05-11 EP EP17727027.9A patent/EP3455359B1/en active Active
- 2017-05-11 SG SG11201810040WA patent/SG11201810040WA/en unknown
- 2017-05-11 KR KR1020187035185A patent/KR102323519B1/ko not_active Expired - Fee Related
- 2017-05-11 TW TW106115604A patent/TWI757291B/zh not_active IP Right Cessation
- 2017-05-11 US US16/099,986 patent/US11384140B2/en active Active
- 2017-05-11 CA CA3024027A patent/CA3024027A1/en active Pending
- 2017-05-11 IL IL300591A patent/IL300591A/en unknown
- 2017-05-11 TW TW111105103A patent/TWI821905B/zh not_active IP Right Cessation
- 2017-05-11 KR KR1020217035841A patent/KR102439719B1/ko active Active
- 2017-05-11 CN CN202211654230.0A patent/CN115873904A/zh active Pending
- 2017-05-11 CN CN201780034550.7A patent/CN109219660B/zh not_active Expired - Fee Related
- 2017-05-11 EP EP22159835.2A patent/EP4067493A1/en active Pending
-
2018
- 2018-11-11 IL IL262923A patent/IL262923B2/en unknown
- 2018-11-12 CL CL2018003210A patent/CL2018003210A1/es unknown
- 2018-11-12 MX MX2022009674A patent/MX2022009674A/es unknown
-
2021
- 2021-11-01 JP JP2021178542A patent/JP7344949B2/ja active Active
-
2022
- 2022-05-26 US US17/825,793 patent/US20230048658A1/en active Pending
-
2023
- 2023-02-08 AU AU2023200660A patent/AU2023200660B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201810040WA (en) | Direct selection of cells expressing high levels of heteromeric proteins using glutamine synthetase intragenic complementation vectors | |
| SG11201810933QA (en) | Anti-c5 antibodies and uses thereof | |
| SG11201908540PA (en) | Stable antibody formulation | |
| SG11201900955VA (en) | T cell receptors and immune therapy using the same | |
| SG11201906961UA (en) | Polypeptide variants and uses thereof | |
| SG11201906341XA (en) | Improved serum albumin binders | |
| SG11201809089QA (en) | Bispecific binding proteins and uses thereof | |
| SG11201907855QA (en) | Multispecific binding proteins targeting caix, ano1, mesothelin,trop2, cea, or claudin-18.2 | |
| SG11201803958WA (en) | Nucleic acids encoding repetitive amino acid sequences rich in proline and alanine residues that have low repetitive nucleotide sequences | |
| SG11201909777YA (en) | Modulatory polynucleotides | |
| SG11201907638QA (en) | Proteins binding cd33, nkg2d and cd16 | |
| SG11201809700YA (en) | Gdf15 fusion proteins and uses thereof | |
| SG11201907653QA (en) | Compositions and methods for enhanced gene expression | |
| SG11201807286WA (en) | Methods and compositions for transducing lymphocytes and regulated expansion thereof | |
| SG11201407866XA (en) | Method for expression of heterologous proteins using a recombinant negative-strand rna virus vector | |
| SG11201908280SA (en) | "chimeric molecules and uses thereof" | |
| SG11201804161VA (en) | Compositions comprising bacterial strains | |
| SG11201907253VA (en) | Proteins binding bcma, nkg2d and cd16 | |
| SG11201903693QA (en) | Polypeptide variants and uses thereof | |
| SG11201900746RA (en) | Engineered antibodies and other fc-domain containing molecules with enhanced agonism and effector functions | |
| SG11201408095XA (en) | Fibroblast growth factor 21 proteins | |
| SG11201809625RA (en) | 1-tetrahydropyranylcarbonyl-2,3-dihydro-1h-indole compounds for treating cancer | |
| SG11201907645PA (en) | Proteins binding cd123, nkg2d and cd16 | |
| SG11201907648XA (en) | Proteins binding gd2, nkg2d and cd16 | |
| SG11201804704PA (en) | Compositions and methods for decreasing tau expression |